Increasing instances of substandard, falsified and counterfeit medical products continue to pose a major challenge to the global healthcare system which is already suffering from the dire impact of COVID-19. To address this issue, ASPA and Messe Frankfurt India will unite leading experts from
More
Terrassa (Barcelona): Telstar will be exhibiting the latest developments in aseptic technology
SIRIO Group’s global Nutra-Innovation Team is rapidly intensifying efforts to create new formulations in different
Ashfield Engage, part of UDG Healthcare plc, today announced that it has
BARCELONA, Spain and Dundee, UK, a global biopharmaceutical company focused on skin health, today announced a research collaboration with the University
More
Cambridge, UK, CellCentric, aclinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces the appointments
More
New York, Kicking off the season for pharmaceutical professionals to come together digitally (09-27 May, 2022) as well as in-person (17-19 May,
More
GENT, BELGIUM, eTheRNA immunotherapies NV (“eTheRNA”), an mRNA technology discovery and development company with a full platform of integrated capabilities, is pleased
More
London, ATMPS Ltd/Hataali – the leader in blockchain-based data sharing platforms for advanced therapies – announces it has been granted a
More
Symbiosis Pharmaceutical Services Ltd (Symbiosis), a fast-growing contract manufacturing organisation (CMO) specialising in sterile global manufacture of pharmaceuticals, vaccines and
More
The leading European pharmaceutical marketplace now hosts more than 85 000 CTD dossiers for finished dosage formulation products. Compared to
More
NIEL, BELGIUM, eTheRNA Manufacturing, a specialist RNA process developer and manufacturing member of the Belgian eTheRNA group, is introducing a
MoreKarlsruhe/Germany, Romaco Macofar’s Oftalmica was specially developed for aseptic filling of sterile eye drops, nasal sprays and injectables. Meeting all
MoreBARCELONA, Spain, More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease
More
